Education and Training
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: BMS-986460
Eligibility
Inclusion Criteria:
- Participant must have histologically or cytologically confirmed adenocarcinoma of the
prostate.
- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status
0 to 1.
- Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
- Participant must have progressed on androgen deprivation therapy (ADT) and at least
one prior secondary hormonal therapy approved for castration-resistant prostate cancer
(CRPC)
Exclusion Criteria:
- Participant must not have history of brain metastases.
- Participant must not have impaired cardiac function or clinically significant cardiac
disease.
- Participant must not have any significant medical condition, including active or
uncontrolled infection, psychiatric illness, or the presence of laboratory
abnormalities, which places the participant at unacceptable risk or prevent
participation in the study based on Investigator assessment.
Other protocol-defined inclusion/exclusion criteria apply
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Aidan Keil O'Brien
650-723-3046
Not Recruiting